Gentian Diagnostics AS announces its results for the 4th quarter and 2020 preliminary annual results. The highlights include:
* Gentian finished the year with record sales of MNOK 17.2 in the 4Q20 which corresponds to 22 % growth versus 4Q19
* Total sales revenue for the year was MNOK 63.3 representing a 32 % growth (22 % adjusted for currency effects) compared to the same period last year
* Double digit sales growth was achieved for all products and all regions in 2020
* Gentian’s unique PETIA-based SARS-CoV-2 antibody test has reached the next development phase with an estimated launch by the end of 2021
* Encouraging scientific publications on GCAL® in context of COVID-19 patient management have spurred the interest of hospitals and laboratories from all over Europe
Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.com.